Mankind Pharma and Takeda Ink Pact To Market Vonoprazan in India

Mankind Pharma announced that it has signed a non-exclusive patent licensing deal with Takeda, a Japanese pharmaceutical company, to distribute Takeda's drug Vonoprazan in India.

Mankind Pharma has been given permission to introduce a new medication for treating Gastroesophageal Reflux Disease (GERD) under its own brand. Vonoprazan is a potassium-competitive acid blocker (P-CAB) utilized for managing acid-related ailments, such as GERD.

The medication works well for treating ailments like erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis, and Helicobacter pylori elimination. Mankind Pharma is giving importance to in-licensing agreements to introduce new treatments and enhance the domestic formulation business.

The company from Delhi has signed in-licensing deals with Novartis for the heart failure medication Neptaz. A licensing agreement was signed in May 2024 with AstraZeneca to distribute the inhaled corticosteroid drug Symbicort in India.

Indian pharmaceutical companies such as Mankind are utilizing in-licensing to promote and distribute innovative medications from multinational corporations in the Indian market. Royalty is paid based on sales. MNCs utilize licensing to widen the reach of their products in the Indian market with the assistance of local companies' nationwide sales network.

“By introducing Vonoprazan, we aim to address a significant medical need and improve the quality of life for those suffering from acid-related illnesses with a new and advanced option for managing acid-related disorders, potentially offering improved health outcomes and quality of life,” said M Ramesh, EVP, Global Business Development, Mankind Pharma.